Boston Scientific (BSX) EBITDA (2009 - 2026)

Boston Scientific has disclosed EBITDA across 18 years of filings, most recently posting $1.2 billion for Q2 2026.

• In Q2 2026, EBITDA rose 43.83% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $4.2 billion (up 31.89% YoY), while the FY2025 annual figure was $3.6 billion, up 38.8% from the prior year.
• EBITDA came in at $1.2 billion for Q2 2026 at Boston Scientific, up from $1.1 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.2 billion in Q2 2026 to a low of $358.0 million in Q3 2022.
• Average EBITDA over 5 years is $693.7 million, with a median of $675.0 million recorded in 2024.
• The largest YoY upside for EBITDA was 123.33% in 2022 against a maximum downside of 7.49% in 2022.
• Over 5 years, EBITDA stood at $402.0 million in 2022, then surged by 45.27% to $584.0 million in 2023, then rose by 15.58% to $675.0 million in 2024, then gained by 22.22% to $825.0 million in 2025, then surged by 42.79% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $1.2 billion in Q2 2026, $1.1 billion in Q1 2026, and $825.0 million in Q4 2025.